CHRO
AMEXChannel Therapeutics Corporation
Channel Therapeutics Corporation (CHRO) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on AMEX. There were no new wire items for CHRO in the last 30 days. The most recent was published Jul 10, 2025.
Latest news
25 items- SECSEC Form D filed by Channel Therapeutics CorporationD - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum ContagiosumZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for high un
- SECSEC Form SCHEDULE 13G filed by Channel Therapeutics CorporationSCHEDULE 13G - Pelthos Therapeutics Inc. (0001919246) (Subject)
- INSIDERSEC Form 4 filed by Director Baxter Richard B4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Director Greenleaf Peter4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Director Pauls Matthew4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by CFO, Treas & Secty Francis Knuettel Ii4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Director Davis Todd C4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Director Friedberg Ezra M4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 4 filed by Director Malamut Richard4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 3 filed by new insider Greenleaf Peter3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pauls Matthew3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 3 filed by new insider Baxter Richard B3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Channel Therapeutics CorporationSCHEDULE 13D/A - Pelthos Therapeutics Inc. (0001919246) (Subject)
- INSIDERDirector Friedberg Ezra M converted options into 80,000 shares (SEC Form 4)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERChief Financial Officer Francis Knuettel Ii converted options into 10,000 shares (SEC Form 4)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERDirector Davis Todd C converted options into 1,500,000 shares (SEC Form 4)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECSEC Form SCHEDULE 13D filed by Channel Therapeutics CorporationSCHEDULE 13D - Pelthos Therapeutics Inc. (0001919246) (Subject)
- INSIDERLarge owner Ligand Pharmaceuticals Inc converted options into 1,500,000 shares (SEC Form 4)4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ligand Pharmaceuticals Inc3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- SECChannel Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
- PRPelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private PlacementThe combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me
- PRChannel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private PlacementFREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the "NYSE American") in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and in
- SECSEC Form DEFM14C filed by Channel Therapeutics CorporationDEFM14C - Channel Therapeutics Corp (0001919246) (Filer)
- PRChannel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo ModelsFREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. "We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and ch
CHRO FAQ
6 questionsWhat is the latest news on CHRO?
Quantisnow has not tracked any new filings, ratings or press releases for CHRO in the last 30 days. The most recent wire item was published on July 10, 2025.Where does CHRO stock trade?
Channel Therapeutics Corporation (CHRO) is listed on AMEX.What sector and industry is CHRO in?
Channel Therapeutics Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Channel Therapeutics Corporation go public?
Channel Therapeutics Corporation (CHRO) completed its IPO in 2024.What companies are similar to CHRO?
Notable peers in the same industry include AMGN (Amgen Inc.), EXEL (Exelixis Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare CHRO side-by-side with any of them on Quantisnow.How can I track CHRO on Quantisnow?
Quantisnow aggregates Channel Therapeutics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CHRO to receive live email and push alerts on every new disclosure.